BLM Genotype

Most people never think about how faithfully their cells copy DNA. A small number, though, inherit a flaw in one of the genes responsible for that proofreading. When both inherited copies of this particular gene are broken, the result is a rare condition marked by poor growth and a striking tendency toward cancer at a young age.

For nearly everyone else, the practical question is what a single broken copy means. This test reads the exact spelling of your BLM (Bloom syndrome RecQ-like helicase) gene and tells you whether you carry a variant that can run in families and influence cancer risk, in ways that depend heavily on which variant you have and which cancer is being considered.

What This Gene Actually Does

The BLM gene sits on chromosome 15 and holds the blueprint for a helicase, a molecular tool that unwinds DNA so it can be copied and mended during repair. It works during the phase of the cell cycle when DNA is being duplicated and chromosomes are being split into two new cells, which is why it matters most in tissues that divide often.

When this helicase is missing or badly weakened, chromosomes become unstable. A classic laboratory sign is a large jump in the exchange of DNA segments between sister chromatids, the two identical copies of a chromosome that a cell makes just before it divides. Scientists call this sister chromatid exchange, and that instability is the underlying reason a loss of BLM function is tied so strongly to cancer.

Bloom Syndrome

The clearest and best-established meaning of a BLM result applies when both copies of the gene are damaged, either two of the same mutation or one different mutation on each copy. That combination causes Bloom syndrome, which brings growth failure that starts before birth, short stature, sun-sensitive skin changes, fertility problems, a mild immune weakness, and in some people diabetes.

The defining feature is a very high lifetime cancer risk, often striking young and sometimes as more than one separate cancer. A registry review of 134 affected people identified a mutation in 125 of them, 64 different mutations in all, many of them recurring founder variants shared within specific populations. If you carry two damaging BLM variants, this test is diagnostic rather than exploratory, and it should be interpreted with a specialist.

The Breast Cancer Question

The most confusing part of a BLM result is what a single damaged copy (carrier status) means for breast cancer, because the evidence points in different directions. An early study in Russia found the truncating Q548X variant in roughly 1.1% of breast cancer cases (17 of 1,498) versus about 0.2% of women without cancer (2 of 1,093), a signal of higher risk in that population.

A much larger follow-up in Poland did not confirm this. The same founder variant appeared in about 0.55% of breast cancer patients and 0.55% of healthy women, an odds ratio of 1.0 (95% CI 0.6 to 1.6), meaning carriers were no more likely to have breast cancer than non-carriers in that cohort. Tumors in carriers looked no different, and the healthy copy of the gene was still present in their tumors, arguing against a dominant, BRCA-style effect.

This is not a true contradiction. A carrier variant is not a simple good-number or bad-number result. Its meaning shifts with the exact variant, the population it appears in, and the specific cancer being studied. A small, exposure-driven, or population-specific signal can look like risk in one dataset and vanish in a larger, more representative one. A pooled analysis across Slavic populations did report an association for the Q548X variant specifically, so a modest population-specific effect cannot be fully ruled out. Read that way, both findings fit: for breast cancer overall, the largest single studies argue a single BLM variant does not meaningfully raise risk, and major guidelines do not list BLM among breast cancer susceptibility genes.

Early-Onset Colorectal Cancer

For colorectal cancer diagnosed at a young age, the carrier evidence is more suggestive but still moderate. Damaging BLM variants turned up more often in people with early-onset colorectal cancer than in comparison groups, and one tumor lost its healthy copy of the gene, the pattern expected if BLM behaves like a protective gene whose loss allows a cancer to grow.

The important caveat is that this appears to be a moderate-to-low effect. Carrying a variant does not mean colorectal cancer is inevitable. It is best read as one input that may justify earlier or more frequent screening, especially alongside a family history of colorectal cancer.

Mesothelioma and Asbestos

Carrier risk looks most convincing for mesothelioma, a cancer of the lining around the lungs and abdomen that is strongly tied to asbestos. In one study, 7 of 155 mesothelioma patients carried a damaging germline BLM variant, far more than expected from general-population databases.

The signal appears strongest in the setting of asbestos exposure, suggesting the variant and the exposure combine to raise risk rather than the gene acting alone. For someone with a known asbestos history, a positive BLM result may be worth discussing with a clinician, though current mesothelioma guidelines do not yet define a specific change in management for carriers.

Metastatic Prostate Cancer

Truncating germline BLM variants have also been found more often in men with metastatic prostate cancer than expected, in a large clinical testing dataset. As with the other cancers, this is an enrichment signal rather than a precise risk estimate, but it is a reason a positive result should feed into prostate screening decisions for men.

A One-Time Test You Act On for Years

Your BLM genotype is fixed at conception and does not change over your lifetime, so this is a once-and-done test. A confirmed, well-interpreted result never needs to be repeated for the same variants, and there is no trend to track the way there is with a changeable blood marker.

The value comes from what you do with the answer over the following years. If you carry a damaging variant, the ongoing testing that matters is phenotype monitoring: age-appropriate and sometimes earlier cancer screening tailored to the risks above, chosen with a clinician. Do not wait for a cancer to appear to learn you carry the variant. Learn the genotype once, then let it drive earlier and more attentive screening.

When a Result Can Mislead You

Because this is a DNA test rather than a changeable lab value, the ways it can mislead are different from ordinary bloodwork.

• Panel coverage: the assay only detects the variants it is designed to read. A negative result lowers the odds you carry a common variant, but it does not rule out rarer changes in the gene that the test was not built to find.
• Ancestry matters: founder variants differ by population, including Ashkenazi Jewish, Japanese, Slavic, and Spanish-ancestry groups. A test aimed at one population's common variant can miss disease in someone of a different background.
• Uncertain variants: a result may flag a change whose meaning is not yet known, which is neither a clean positive nor a clean negative and needs expert interpretation.
• Germline versus tumor: this test assumes normal inherited DNA. Findings from tumor tissue behave differently and are not the same as an inherited carrier result.

What to Do With an Unexpected Result

A positive or ambiguous result is a starting point for a workup, not a verdict. If the finding came from a chip-based method, a confirmation by direct gene sequencing may be warranted before acting. If two damaging variants are found, or a phenotype suggests Bloom syndrome, cytogenetic testing for sister chromatid exchange and evaluation for related look-alike conditions caused by other genes in the same repair complex can clarify the picture.

The most useful next step is usually a referral to a genetic counselor or medical geneticist, who can match the exact variant, your ancestry, and your family and exposure history to a screening plan. That plan might include earlier colorectal screening, prostate screening for men, and heightened attention if there is any asbestos exposure. It should also start a conversation with biological relatives, who may share the variant.